Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs ADMA Biologics, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Ionis Pharmaceuticals, Inc. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, Ionis Pharmaceuticals consistently outspent ADMA Biologics, with SG&A expenses peaking at approximately 354% higher in 2020. However, ADMA Biologics has shown a steady increase in its SG&A expenses, growing by over 1,100% from 2014 to 2023. This trend reflects the company's expansion efforts and increasing operational activities. Meanwhile, Ionis Pharmaceuticals experienced a more volatile pattern, with a significant drop in 2021, followed by a resurgence in 2023. These insights highlight the dynamic nature of financial management in the biotech industry, where strategic spending can be a key driver of growth and innovation.